Physician profile
Richard S Lemons
NPI 1073692646
$753,095.74
in general payments reported to CMS, 2019-2025
8 companies · $220K in 2025
The $220K reported for 2025 was more than what 99% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,104 · 2021: $315 · 2022: $28K · 2023: $245K · 2024: $254K · 2025: $220K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $514K · Travel and Lodging: $129K · Consulting Fee: $65K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $513,929.52 |
| Travel and Lodging | $128,969.60 |
| Consulting Fee | $65,422.01 |
| Food and Beverage | $10,645.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $553,674.62 | 2022-2025 | Hemgenix, Idelvion, Hemgenix |
| Novo Nordisk INC | $187,490.48 | 2022-2025 | Alhemo, Esperoct, Rebinyn |
| Novartis Pharmaceuticals Corporation | $5,728.55 | 2019 | |
| Pfizer INC. | $5,512.09 | 2023 | |
| Genzyme Corporation | $375.00 | 2019 | |
| Melinta Therapeutics, LLC | $315.00 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lemons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.